Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

Stock futures edged lower on Monday due to trade war concerns and the upcoming 25% levy on non-US cars. President Trump has ...

Vaxcyte plunges 56% even though its VAX-24 pneumonia vaccine shows positive phase two results in infants. Read more here.

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At ...

Vaxcyte (PCVX) shared topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, ...

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect ...

To protect your child, their doctor will give them the pneumococcal conjugate vaccine (PCV). "This is a great example of a vaccine that protects against invasive disease from a ba ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new ...

The following is a list of major prescription drugs whose ingredients or components are imported into the United States from the European Union, based on U.S. Food and Drug Administration import data ...

Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to ...

Prevnar revenues were in line with the Zacks ... Paxlovid revenues were $727 million in the quarter against negative $3.2 billion in the year-ago quarter. Paxlovid revenues beat the Zacks ...